| Year |
Citation |
Score |
| 2018 |
Luderman KD, Conroy JL, Free RB, Southall N, Ferrer M, Sanchez-Soto M, Moritz AE, Willette BKA, Fyfe TJ, Jain P, Titus S, Hazelwood LA, Aube J, Lane JR, Frankowski KJ, et al. Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites. Molecular Pharmacology. PMID 30068735 DOI: 10.1124/Mol.118.113175 |
0.405 |
|
| 2016 |
Luderman KD, Conroy JL, Free RB, Southall NT, Ferrer M, Aubé J, Frankowski KJ, Sibley DR. Structurally Diverse Positive Allosteric Modulators of the D1 Dopamine Receptor Potentiate G‐Protein and β‐Arrestin‐Mediated Signaling The Faseb Journal. 30. DOI: 10.1096/Fasebj.30.1_Supplement.931.9 |
0.358 |
|
| 2015 |
Dix AV, Conroy JL, George Rosenker KM, Sibley DR, Appella DH. PNA-Based Multivalent Scaffolds Activate the Dopamine D2 Receptor. Acs Medicinal Chemistry Letters. 6: 425-9. PMID 25893044 DOI: 10.1021/Ml500478M |
0.354 |
|
| 2015 |
Conroy JL, Free RB, Sibley DR. Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor. Acs Chemical Neuroscience. 6: 681-92. PMID 25660762 DOI: 10.1021/Acschemneuro.5B00020 |
0.403 |
|
| 2015 |
Meade JA, Free RB, Miller NR, Chun LS, Doyle TB, Moritz AE, Conroy JL, Watts VJ, Sibley DR. (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling. Psychopharmacology. 232: 917-30. PMID 25231919 DOI: 10.1007/S00213-014-3726-8 |
0.375 |
|
| 2014 |
Free RB, Chun LS, Moritz AE, Miller BN, Doyle TB, Conroy JL, Padron A, Meade JA, Xiao J, Hu X, Dulcey AE, Han Y, Duan L, Titus S, Bryant-Genevier M, et al. Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor. Molecular Pharmacology. 86: 96-105. PMID 24755247 DOI: 10.1124/Mol.113.090563 |
0.418 |
|
| 2014 |
Xiao J, Free RB, Barnaeva E, Conroy JL, Doyle T, Miller B, Bryant-Genevier M, Taylor MK, Hu X, Dulcey AE, Southall N, Ferrer M, Titus S, Zheng W, Sibley DR, et al. Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists. Journal of Medicinal Chemistry. 57: 3450-63. PMID 24666157 DOI: 10.1021/Jm500126S |
0.336 |
|
| 2013 |
Conroy JL, Nalwalk JW, Phillips JG, Hough LB. CC12, a P450/epoxygenase inhibitor, acts in the rat rostral, ventromedial medulla to attenuate morphine antinociception. Brain Research. 1499: 1-11. PMID 23298831 DOI: 10.1016/J.Brainres.2012.12.030 |
0.552 |
|
| 2013 |
Bergman J, Roof RA, Furman CA, Conroy JL, Mello NK, Sibley DR, Skolnick P. Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 16: 445-58. PMID 22827916 DOI: 10.1017/S1461145712000661 |
0.334 |
|
| 2011 |
Hough LB, Nalwalk JW, Yang J, Conroy JL, VanAlstine MA, Yang W, Gargano J, Shan Z, Zhang SZ, Wentland MP, Phillips JG, Knapp BI, Bidlack JM, Zuiderveld OP, Leurs R, et al. Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic. Pain. 152: 878-87. PMID 21316152 DOI: 10.1016/J.Pain.2011.01.001 |
0.576 |
|
| 2010 |
Conroy JL, Fang C, Gu J, Zeitlin SO, Yang W, Yang J, VanAlstine MA, Nalwalk JW, Albrecht PJ, Mazurkiewicz JE, Snyder-Keller A, Shan Z, Zhang SZ, Wentland MP, Behr M, et al. Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. Nature Neuroscience. 13: 284-6. PMID 20139973 DOI: 10.1038/Nn.2497 |
0.572 |
|
| Show low-probability matches. |